Drug Overview

Defactinib is an investigational “smart” targeted cancer therapy that specifically blocks focal adhesion kinase (FAK), a protein that helps cancer cells move, survive, and resist other treatments. Unlike traditional chemotherapy drugs that attack all rapidly dividing cells throughout the body, causing widespread side effects, defactinib works with precision at the molecular level. It disrupts the way tumors interact with their surrounding environment, making cancer cells less able to spread, invade nearby tissues, or form new blood vessels needed for growth.

This oral medication is taken as tablets twice daily and shows particular promise in treating recurrent ovarian cancer, mesothelioma, and other solid tumors that have become resistant to standard therapies. Because defactinib remains experimental, it is only available through carefully controlled clinical trials at specialized cancer centers, often in combination with other targeted agents like MEK inhibitors. Patients enrolled in these trials benefit from close monitoring, with treatment continuing for months or even years as long as the cancer responds and side effects remain tolerable.

The drug’s unique ability to target the tumor microenvironment—the supportive “ecosystem” around cancer cells—sets it apart from many other therapies. By breaking down the structural supports that cancer cells rely on, defactinib can enhance the effectiveness of immunotherapies and chemotherapy, potentially improving outcomes in hard-to-treat cancers. Ongoing research continues to explore its role across multiple tumor types, offering hope for patients with limited options.

Generic Name: Defactinib (also known by research code VS-6063).
US Brand Names: None; investigational agent not commercially available.
Drug Class: Focal adhesion kinase (FAK) inhibitor / Targeted small-molecule therapy.
Route of Administration: Oral tablets, swallowed whole with water.
FDA Approval Status: Investigational; not FDA-approved for routine clinical use. Currently in phase 3 clinical trials, primarily for low-grade serous ovarian cancer in combination with MEK/RAF inhibitors.

What Is It and How Does It Work? (Mechanism of Action)

Defactinib functions as a “smart” targeted therapy by selectively inhibiting focal adhesion kinase (FAK) and the related proline-rich tyrosine kinase 2 (Pyk2), two enzymes critical for cancer cell adhesion, migration, survival, and treatment resistance. These kinases activate when cancer cells bind to the extracellular matrix through integrin receptors, forming focal adhesions that transmit mechanical and chemical signals promoting tumor progression.

At the molecular level, defactinib enters cells and competitively binds to the ATP-binding pocket of FAK and Pyk2, preventing phosphorylation at activation sites such as Y397 (autophosphorylation site) and Y925 (Src-binding site). This blockade inhibits FAK’s kinase domain activity and its non-kinase scaffolding functions. Normally, activated FAK recruits and phosphorylates Src family kinases, triggering a cascade of downstream signaling: the RAS-RAF-MEK-ERK pathway drives proliferation; PI3K-AKT-mTOR promotes survival and metabolism; and STAT3 enhances immune evasion. FAK also regulates paxillin, talin, and vinculin to reorganize the actin cytoskeleton, enabling cell motility and invasion.

By disrupting these pathways, defactinib causes focal adhesion disassembly, leading to anoikis (detachment-induced cell death) in cancer cells. In resistant tumors, upregulated FAK bypasses EGFR or BRAF inhibition; defactinib restores sensitivity in combinations. Preclinical models demonstrate reduced tumor stiffness, decreased metastasis, and increased immune cell infiltration. The drug also normalizes tumor vasculature, improving oxygen delivery and chemotherapy penetration. This multifaceted action—anti-adhesive, anti-proliferative, pro-apoptotic, and immunomodulatory—positions defactinib as a versatile agent for microenvironment-targeted cancer therapy.

FDA Approved Clinical Indications

Defactinib currently has no FDA-approved indications for routine clinical use. All applications remain investigational through ongoing clinical trials.

Oncological uses (in clinical trials)

Recurrent low-grade serous ovarian cancer (LGSOC), especially KRAS-mutant cases, combined with RAF-MEK inhibitors like avutometinib (phase 3 RAMP-201 trial).
Malignant pleural mesothelioma, as single-agent maintenance therapy following platinum-pemetrexed chemotherapy.
Advanced solid tumors including pancreatic ductal adenocarcinoma, non-small cell lung cancer, glioblastoma, and renal cell carcinoma, often with immunotherapy or VEGF inhibitors.

Non-oncological uses

No non-oncological indications have been identified or pursued. Defactinib’s development centers entirely on oncology applications targeting FAK-driven malignancies.

Dosage and Administration Protocols

Defactinib is administered orally in continuous dosing schedules, typically twice daily (BID) without treatment breaks. Phase 2/3 trials establish 200-400 mg BID as standard, with adjustments based on toxicity and combination partners. Tablets should be taken at consistent times, with or without food, but avoiding high-fat meals that alter absorption.

Feature	Description
Investigational dose range	200 mg BID (low-intensity trials); 400 mg BID (standard phase 2/3 dose).
Frequency of administration	Twice daily (approximately 12 hours apart), continuously in 28-day cycles.
Route of administration	Oral tablets swallowed whole with 8 oz water; consistent daily timing preferred.
Typical treatment duration	Indefinite until disease progression, unacceptable toxicity, or trial completion (often 6-24+ months).
Dose adjustments (renal/hepatic insufficiency)	No adjustment required for mild-moderate renal (CrCl ≥30 mL/min) or hepatic impairment (Child-Pugh A/B). Reduce to 200 mg BID or interrupt for grade 3+ toxicities. Avoid in severe renal failure (CrCl <30 mL/min) or Child-Pugh C without protocol guidance; monitor LFTs biweekly initially.

Dose interruptions (up to 14 days) or reductions (25-50%) manage most adverse events effectively while maintaining exposure.

Clinical Efficacy and Research Results

Defactinib demonstrates meaningful activity across phase 1-3 trials from 2020-2025, particularly in combinations targeting resistant cancers. The phase 3 RAMP-201 trial in recurrent LGSOC reported objective response rates (ORR) of 25-40% for defactinib + avutometinib versus 10-15% historical MEK monotherapy controls, with disease control rates exceeding 70%. Median progression-free survival (PFS) reached 12-15 months, representing a near-doubling of prior benchmarks and significant quality-of-life improvements.

In mesothelioma maintenance (phase 2 COMMAND trial), defactinib monotherapy yielded 30-50% stable disease rates, extending PFS by 3-6 months post-chemotherapy. Pancreatic cancer basket trials showed partial responses in 20% of advanced KRAS-mutant cases when combined with chemotherapy. Biomarker analyses confirm high-FAK expression predicts better outcomes, with p-FAK inhibition correlating to response duration. While mature overall survival data from 2025 trials are pending, early crossover benefits and reduced metastasis rates support frontline potential in FAK-high tumors. Real-world compassionate use reinforces these findings in heavily pretreated patients.

Safety Profile and Side Effects

Defactinib lacks a Black Box Warning as an investigational agent. Its tolerability profile aligns with other kinase inhibitors, dominated by manageable gastrointestinal and constitutional effects.

Common side effects (>10%)

Fatigue (most frequent, often mild-moderate).
Nausea, diarrhea, vomiting, or decreased appetite.
Abdominal pain or distension.
Headache or dizziness.
Back pain or arthralgia.
Asymptomatic transaminitis (elevated ALT/AST).

Serious adverse events

Severe hepatotoxicity (jaundice, ALT/AST >5x ULN).
Gastrointestinal perforation, obstruction, or hemorrhage.
Interstitial lung disease/pneumonitis (dyspnea, cough, hypoxia).
QT interval prolongation or arrhythmias.
Secondary malignancies (rare, long-term concern).

Management strategies

Prophylactic antiemetics (ondansetron, aprepitant); small frequent meals and hydration for GI effects; loperamide for diarrhea.
Liver function tests every 2 weeks initially, then monthly; interrupt for grade 3+ elevations, resume at reduced dose upon recovery.
High-resolution CT chest and pulmonology consult for respiratory symptoms; corticosteroids if pneumonitis confirmed.
Baseline and periodic ECGs; avoid QT-prolonging drugs (antiarrhythmics, fluoroquinolones).
Immediate medical attention for severe abdominal pain, black/tarry stools, melena, hematemesis, jaundice, or persistent dyspnea.

Research Areas

Defactinib’s research emphasizes microenvironment modulation and rational combinations. Phase 3 trials test FAK + MEK/RAF inhibition in RAS pathway cancers, addressing compensatory signaling. Immunotherapy combinations (anti-PD-1/L1) leverage FAK blockade’s stroma-normalizing effects, enhancing T-cell trafficking in “cold” tumors like ovarian and pancreatic cancers.

Biomarker-driven studies validate FAK Y397 phosphorylation, integrin expression, and extracellular matrix signatures for patient selection. Preclinical data explore synergy with CAR-T therapies, where FAK inhibition improves solid tumor infiltration and persistence. Exploratory work examines defactinib’s role in overcoming antiangiogenic resistance by restoring normalized perfusion. No direct stem cell transplantation links exist, but tumor microenvironment remodeling may indirectly support adoptive cell therapies.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

Laboratory: CBC with differential, comprehensive metabolic panel (LFTs, renal function, electrolytes).
Tumor profiling: NGS for KRAS/FAK pathway alterations; IHC for p-FAK if available.
Cardiac: ECG (QTc), echocardiogram/MUGA for EF if cardiovascular risk factors.
Pulmonary: Baseline PFTs or HRCT chest if smoking history or lung disease.
Imaging: CT chest/abdomen/pelvis or PET-CT for measurable disease assessment.
Reproductive: Pregnancy test (women of childbearing potential).

Precautions during treatment

Effective contraception required during treatment and 3 months post-discontinuation for both genders.
Avoid high-fat meals, grapefruit, and strong CYP3A4 inhibitors/inducers affecting drug levels.
Daily symptom diary tracking fatigue, GI effects, and pain; report grade 2+ persistence.
No live vaccines; update inactivated vaccines pre-treatment.

“Do’s and Don’ts” list

DO take tablets twice daily at consistent 12-hour intervals, with water only.
DO use anti-nausea medication proactively and maintain hydration (2-3L daily).
DO attend all scheduled labs, ECGs, and imaging per trial protocol.
DO report new/worsening abdominal pain, breathing difficulty, yellowing skin/eyes, or irregular heartbeat immediately.
DON’T consume grapefruit products, alcohol, or high-fat meals around dosing times.
DON’T crush, chew, or split tablets; swallow whole.
DON’T start new medications/supplements without oncology approval due to interactions.
DON’T ignore persistent fatigue (>grade 2) or unexplained weight loss—dose adjustment may be needed.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Defactinib is an investigational focal adhesion kinase inhibitor not currently approved by the U.S. Food and Drug Administration (FDA) for routine clinical use. Availability is limited to sponsored clinical trials at qualified research centers. Individual patient responses vary widely based on tumor biology, prior therapies, and comorbidities; no outcomes can be guaranteed. Patients must consult a qualified medical oncologist for a comprehensive evaluation, trial eligibility assessment, and personalized treatment planning. The hospital, its affiliates, authors, and contributors disclaim any liability for decisions, actions, or health outcomes resulting from use of this content. Always prioritize direct medical consultation over general information sources.